James Briggs is currently the Emerging Technologies Group Lead at NewLimit, where they contribute to the discovery engine by developing technology for functional genomic screens of epigenetic reprogramming factors. Previously, they served as a Postdoctoral Research Fellow at the Broad Institute, focusing on scalable pooled screens to program human embryonic cells into blood progenitors. They earned a Ph.D. in Biology from Harvard Medical School, where their research utilized single cell transcriptomics to advance understanding of embryo development. Their academic journey began with a Bachelor of Science (Hons) degree in Biological and Biomedical Sciences from The University of Queensland.
This person is not in the org chart
This person is not in any teams
This person is not in any offices